First AI-designed drug hits Phase 3; Insilico releases 4B kinase specialist model
CatAstro_Piyush · x · 2026-09-10
Insilico Medicine announced that Rentosertib, the first AI-designed drug, has entered Phase 3 trials. It inhibits TNIK, a kinase that acts as a molecular switch inside cells.
The core challenge with kinases is selectivity: their binding pockets are remarkably similar, so a molecule designed for one may hit others. To address this, the company also released InsilicoMMAI-4B-Chem-Kinome, a 4B-parameter specialist language model claiming SOTA+ performance across 31 kinase targets.
More from AGI Musings
- AI safety voices blur real risk with extinction talk, warns researcher: wrong fear is the worst fear — Dr_Atoosa · 2026-09-11
- AI safety insider: cheap extinction-risk talk is destroying the public's imagination of AI — Dr_Atoosa · 2026-09-11
- New essay argues scaling laws originate in data structure, not architectures — gleech · 2026-09-11
- Seeking Optimism: Reddit Debates Whether Superintelligence Means Extinction — joshlove182 · 2026-09-11
- BlackHC: x-risk unlikely with current models, but rises sharply within a decade without changes — BlackHC · 2026-09-11
- Why AI doomerism splits by generation: Xennial optimism vs Zoomer fear — nptacek · 2026-09-11